Teva Pharmaceutical Industries (TEVA) EBT (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly EBT came in at -$455.0 million in Q2 2026, down 324.14% YoY from $203.0 million in Q2 2025, and down 204.12% on a QoQ basis from $437.0 million in Q1 2026.
Teva Pharmaceutical Industries (TEVA) EBT (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of EBT data on file, last reported at -$455.0 million in Q2 2026.
- Quarterly EBT fell 324.14% year-over-year to -$455.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $708.0 million (up 1056.76% YoY) and the FY2025 annual result came in at $1.2 billion, up 195.25% from the prior year.
- EBT fell to -$455.0 million in Q2 2026, from $437.0 million in the prior quarter.
- In the past five years, EBT ranged from a high of $646.0 million in Q3 2025 to a low of -$1.8 billion in Q4 2023.
- A 5-year average of -$288.6 million and a median of -$246.5 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT sank 774.31% — and 2025, when it surged 299.38%.
- Tracing TEVA's EBT over 5 years: stood at -$1.2 billion in 2022, then plunged by 48.1% to -$1.8 billion in 2023, then surged by 85.93% to -$247.0 million in 2024, then surged by 132.39% to $80.0 million in 2025, then tumbled by 668.75% to -$455.0 million in 2026.
- The last three EBT figures came in at -$455.0 million (Q2 2026), $437.0 million (Q1 2026), and $80.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.64 Bn | 2.15 Bn | -455.00 Mn |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.74 Bn | 22.95 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.26 Bn | 19.60 Bn | 683.80 Mn | 372.70 Mn |
| 6 | Viatris | 18.85 Bn | 17.96 Bn | 1.46 Bn | -64.00 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 162.20 Mn |
| 8 | Elanco Animal Health | 12.15 Bn | 11.62 Bn | 798.00 Mn | 56.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.28 Bn | 7.62 Bn | 397.90 Mn | -1.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -455.00 Mn |
| Mar 31, 2026 | 437.00 Mn |
| Dec 31, 2025 | 80.00 Mn |
| Sep 30, 2025 | 646.00 Mn |
| Jun 30, 2025 | 203.00 Mn |
| Mar 31, 2025 | 294.00 Mn |
| Dec 31, 2024 | -247.00 Mn |
| Sep 30, 2024 | -324.00 Mn |
| Jun 30, 2024 | -246.00 Mn |
| Mar 31, 2024 | 467.00 Mn |
| Dec 31, 2023 | -1.76 Bn |
| Sep 30, 2023 | 64.00 Mn |
| Jun 30, 2023 | -923.00 Mn |
| Mar 31, 2023 | -272.00 Mn |
| Dec 31, 2022 | -1.19 Bn |
| Sep 30, 2022 | 171.00 Mn |
| Jun 30, 2022 | -1.18 Bn |
| Mar 31, 2022 | -971.00 Mn |
| Dec 31, 2021 | -175.00 Mn |
| Sep 30, 2021 | 382.00 Mn |